These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 16397019

  • 21. HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma.
    Learn PA, Yeh IT, McNutt M, Chisholm GB, Pollock BH, Rousseau DL, Sharkey FE, Cruz AB, Kahlenberg MS.
    Cancer; 2005 Jun 01; 103(11):2252-60. PubMed ID: 15834928
    [Abstract] [Full Text] [Related]

  • 22. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
    Kariya S, Ogawa Y, Nishioka A, Moriki T, Ohnishi T, Ito S, Murata Y, Yoshida S.
    Radiat Med; 2005 May 01; 23(3):189-94. PubMed ID: 15940066
    [Abstract] [Full Text] [Related]

  • 23. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
    Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, Löning T.
    Clin Cancer Res; 2006 Jan 01; 12(1):159-68. PubMed ID: 16397038
    [Abstract] [Full Text] [Related]

  • 24. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth.
    Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H.
    Oncogene; 2002 Oct 10; 21(46):7001-10. PubMed ID: 12370822
    [Abstract] [Full Text] [Related]

  • 25. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
    Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K.
    Clin Cancer Res; 2005 Sep 01; 11(17):6382-9. PubMed ID: 16144943
    [Abstract] [Full Text] [Related]

  • 26. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
    Huang H, Groth J, Sossey-Alaoui K, Hawthorn L, Beall S, Geradts J.
    Clin Cancer Res; 2005 Jun 15; 11(12):4357-64. PubMed ID: 15958618
    [Abstract] [Full Text] [Related]

  • 27. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides.
    Weerasinghe P, Garcia GE, Zhu Q, Yuan P, Feng L, Mao L, Jing N.
    Int J Oncol; 2007 Jul 15; 31(1):129-36. PubMed ID: 17549413
    [Abstract] [Full Text] [Related]

  • 28. Survivin expression in breast carcinoma: correlation with apoptosis and prognosis.
    Nassar A, Sexton D, Cotsonis G, Cohen C.
    Appl Immunohistochem Mol Morphol; 2008 May 15; 16(3):221-6. PubMed ID: 18301249
    [Abstract] [Full Text] [Related]

  • 29. Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines.
    Gu L, Chiang KY, Zhu N, Findley HW, Zhou M.
    Exp Hematol; 2007 Jun 15; 35(6):957-66. PubMed ID: 17533050
    [Abstract] [Full Text] [Related]

  • 30. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
    Buchholz TA, Tu X, Ang KK, Esteva FJ, Kuerer HM, Pusztai L, Cristofanilli M, Singletary SE, Hortobagyi GN, Sahin AA.
    Cancer; 2005 Aug 15; 104(4):676-81. PubMed ID: 15981280
    [Abstract] [Full Text] [Related]

  • 31. Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2.
    Real PJ, Cao Y, Wang R, Nikolovska-Coleska Z, Sanz-Ortiz J, Wang S, Fernandez-Luna JL.
    Cancer Res; 2004 Nov 01; 64(21):7947-53. PubMed ID: 15520201
    [Abstract] [Full Text] [Related]

  • 32. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
    Galmarini CM, Treilleux I, Cardoso F, Bernard-Marty C, Durbecq V, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, Di Leo A, Dumontet C.
    Clin Cancer Res; 2008 Jul 15; 14(14):4511-6. PubMed ID: 18628466
    [Abstract] [Full Text] [Related]

  • 33. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells.
    Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, Smithgall T, Fujita DJ, Ethier SP, Jove R.
    Cell Growth Differ; 1997 Dec 15; 8(12):1267-76. PubMed ID: 9419415
    [Abstract] [Full Text] [Related]

  • 34. Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.
    Gogas H, Pectasides D, Kostopoulos I, Lianos E, Skarlos D, Papaxoinis G, Bobos M, Kalofonos HP, Petraki K, Pavlakis K, Bafaloukos D, Fountzilas G.
    Clin Breast Cancer; 2010 Jun 15; 10(3):230-7. PubMed ID: 20497922
    [Abstract] [Full Text] [Related]

  • 35. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
    Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, Brufsky AM, Lembersky BC, Ahrendt GM.
    Cancer; 2010 Mar 15; 116(6):1431-9. PubMed ID: 20131351
    [Abstract] [Full Text] [Related]

  • 36. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A, Posch B, El-Baz M, Mokhtar AA, Susani M, Ghoneim MA, Marberger M.
    J Urol; 2001 May 15; 165(5):1481-7. PubMed ID: 11342901
    [Abstract] [Full Text] [Related]

  • 37. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
    Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao Q, Westlund RE, Zhao S, Bacus S, Spector NL.
    Cancer Res; 2006 Feb 01; 66(3):1640-7. PubMed ID: 16452223
    [Abstract] [Full Text] [Related]

  • 38. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H, Horiguchi J, Takata D, Kikuchi M, Rokutanda N, Nagaoka R, Sato A, Odawara H, Tozuka K, Oyama T, Takeyoshi I.
    Breast Cancer; 2012 Oct 01; 19(4):309-14. PubMed ID: 21725655
    [Abstract] [Full Text] [Related]

  • 39. Naphtho[1,2-b]furan-4,5-dione disrupts Janus kinase-2 and induces apoptosis in breast cancer MDA-MB-231 cells.
    Lin KL, Su JC, Chien CM, Tseng CH, Chen YL, Chang LS, Lin SR.
    Toxicol In Vitro; 2010 Jun 01; 24(4):1158-67. PubMed ID: 20197088
    [Abstract] [Full Text] [Related]

  • 40. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y, Du XL, Wang CJ, Lin DC, Ruan X, Feng YB, Huo YQ, Peng H, Cui JL, Zhang TT, Wang YQ, Zhang H, Zhan QM, Wang MR.
    Gastroenterology; 2012 Mar 01; 142(3):521-530.e3. PubMed ID: 22108192
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.